@article{3034599,
    title = "Diabetes and COVID-19; A Bidirectional Interplay",
    author = "Kazakou, Paraskevi and Lambadiari, Vaia and Ikonomidis, Ignatios and and Kountouri, Aikaterini and Panagopoulos, Georgios and Athanasopoulos, and Stavros and Korompoki, Eleni and Kalomenidis, Ioannis and Dimopoulos, and Meletios A. and Mitrakou, Asimina",
    journal = "FRONTIERS IN ENDOCRINOLOGY",
    year = "2022",
    volume = "13",
    publisher = "Frontiers Media SA",
    doi = "10.3389/fendo.2022.780663",
    keywords = "diabetes; COVID-19; endothelial (dys)function; new onset diabetes;
antidiabetic medication",
    abstract = "There seems to be a bidirectional interplay between Diabetes mellitus
(DM) and coronavirus disease 2019 (COVID-19). On the one hand, people
with diabetes are at higher risk of fatal or critical care unit-treated
COVID-19 as well as COVID-19 related health complications compared to
individuals without diabetes. On the other hand, clinical data so far
suggest that the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) may result in metabolic dysregulation and in impaired
glucose homeostasis. In addition, emerging data on new onset DM in
previously infected with SARS-CoV-2 patients, reinforce the hypothesis
of a direct effect of SARS-CoV-2 on glucose metabolism. Attempting to
find the culprit, we currently know that the pancreas and the
endothelium have been found to express Angiotensin-converting enzyme 2
(ACE2) receptors, the main binding site of the virus. To move from bench
to bedside, understanding the effects of COVID-19 on metabolism and
glucose homeostasis is crucial to prevent and manage complications
related to COVID-19 and support recovering patients. In this article we
review the potential underlying pathophysiological mechanisms between
COVID-19 and glucose dysregulation as well as the effects of
antidiabetic treatment in patients with diabetes and COVID-19."
}